The bridge to improved patient outcomes.

Addressing unmet clinical needs and enabling precision medicine through the proprietary application of molecular profiling.

Actionable Intelligence

Our tests provide physicians with actionable intelligence to develop personalized treatment plans, leading to improved patient outcomes. By targeting clinically challenging problems that are underserved, or unaddressed, by existing tests, we seek to reduce patient misdiagnosis, mistreatment, and overtreatment. These clinical benefits improve patient care, enhance physician insight, and deliver healthcare savings.

The first objective proteomic test to differentiate between malignant melanomas and benign nevi
The first and only test to predict chemoradiotherapy responsiveness in patients with esophageal cancer
Available Early 2019

New River Labs is the leading provider of mass spectrometry imaging based diagnostic and prognostic tests designed to address clinically challenging problems and improve patient care.

Molecular Profiling Technology Icon

Molecular Profiling

Our molecular profiling technology, histology guided mass spectrometry (HGMS), is a proprietary application of mass spectrometry imaging. We evaluate the proteomic contents of targeted cells and develop a molecular snapshot of the active state of the cells. Through the combination of HGMS profiling and machine learning algorithms, we develop a spectral fingerprint to aid in clinical decision making, including disease diagnosis and the evaluation of treatment responsiveness.

Research & Development Icon

Research & Development

Our research and development efforts are focused on the identification and qualification of new pipeline opportunities. We apply our proprietary HGMS technology platform to these areas of clinical unmet need to develop novel diagnostic and prognostic tests. We establish collaborative research partnerships with principal investigators and key opinion leaders during test development. Our Research Advisors enhance our ability to identify new pipeline opportunities, and we are actively pursuing new clinical applications for our technology.